We observed early acute lung injury (ALI) after a switch from veno-arterial extracorporeal life support (VA-ECLS) to longterm mechanical circulatory support (MCS). The aim of our study was to analyse the frequency, impact on mortality and characteristics of patients presenting ALI after MCS implantation in the bridge-to-bridge (BTB) strategy.
INTRODUCTION
Patients suffering from cardiogenic shock may require shortterm extracorporeal life support (ECLS) for haemodynamic stabilization and end-organ recovery [1] [2] [3] . Thus, ECLS provides some time to define subsequent treatment strategies [4] , which may include bridging the patient to recovery, transplantation or long-term mechanical circulatory support (MCS). This latter bridge-to-bridge (BTB) strategy appears to be the sole treatment option for patients who cannot be weaned from support, who do not benefit from a timely graft or who are not candidates for heart transplantation [1] .
In our institution, we use veno-arterial (VA)-ECLS as a primary device for patients suffering from refractory cardiogenic shock. In patients who were subsequently bridged to a long-term MCS device, we have observed several cases of fulminant pulmonary oedema occurring within minutes or hours after implantation. This disastrous complication is poorly acknowledged in the literature. Therefore, we undertook the present study to evaluate the incidence, outcomes and risk factors for postimplant acute lung injury (ALI) in patients undergoing long-term MCS device implantation after VA-ECLS.
PATIENTS AND METHODS

Patient selection
We reviewed all consecutive patients who suffered refractory cardiogenic shock and who were bridged to long-term MCS in our institution between January 2004 and March 2012.
Only patients undergoing peripheral or central VA-ECLS were included. Patients who were supported using another type of short-term device (such as percutaneous centrifugal or transaortic axial pumps) were excluded. Furthermore, only patients who were directly bridged from VA-ECLS to a long-term device were included. Thus, patients who could initially be weaned from VA-ECLS, but who required subsequent implantation of a long-term device, were not included.
Exracorporeal membrane oxygenation management
VA-ECLS was instituted either in our hospital or in referring hospitals before prompt transfer to our institution, using a dedicated mobile unit. In these latter patients, ECLS was always implanted peripherally. Patient management during VA-ECLS has been detailed in previous reports from our group [5] .
Pulmonary oedema while under VA-ECLS was diagnosed on clinical and/or radiographic signs. Its management was gradual and included: fluid depletion using diuretics and/or haemodiafiltration, inotrope infusion and intra-aortic balloon pump counterpulsation, mechanical ventilation and switching peripheral ECLS to central canulation with, eventually, additional venting lines to unload either the left ventricle or the pulmonary artery.
Diagnosis of infectious pneumonia was considered only if bacteriological proof was provided by deep lung harvesting. In the case of positive results, intravenous antibiotherapy was undertaken according to institutional guidelines based on international recommendations [6] .
After end-organ recovery, weaning trials were undertaken daily as described previously [7] . Patients who could not be weaned from ECLS and who were not eligible for cardiac transplantation or who did not receive a donor heart after 96 h of national high emergency listing were evaluated for the implantation of a long-term MCS device. Patients who had ongoing clinical or radiographic pulmonary oedema or pneumonia were temporary contraindicated for long-term MCS implantation. However, mechanical ventilation was not considered a contraindication for the implantation of a long-term MCS device.
Long-term mechanical circulatory support
Long-term MCS devices implanted after VA-ECLS included left ventricular assist devices (LVADs), paracorporeal biventricular assist devices (BiVAD) and the total artificial heart (TAH). These long-term devices used either pulsatile or continuous flow pumps.
Early postimplant ALI was retrospectively defined as the occurrence of clinical and/or radiographic signs of severe pulmonary oedema within 48 h after MCS implantation and associated with a PaO 2 /FiO 2 ratio <200 and/or requiring veno-venous (VV)-ECMO or VA-ECLS. Implantation of VA-ECLS solely for temporary right ventricular support after failed LVAD implantation was not considered as ALI.
Data collection and statistical analysis
Patient clinical and biological data were entered prospectively into a computerized database. This database was reviewed to extract patient data prior to VA-ECMO support, during VA-ECMO support and after switching to long-term MCS.
Approval of the Ethics Board of our hospital was obtained. Written informed consent for every data analysis was not obtained according to French legislation, because this observational study did not modify existing diagnostic or therapeutic strategies.
Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Continuous variables were expressed as median with the interquartile range and compared using the Mann-Whitney test. Categorical variables, expressed as percentages, were analysed using Chi-square or Fisher's exact tests. Survival data were analysed using standard Kaplan-Meier actuarial techniques and compared using the non-parametric log-rank test.
Preoperative risk factors for postimplant ALI were determined using univariate logistic regression. A univariate Cox proportional hazard model was utilized to determine the impact of ALI on survival while on long-term mechanical support. No multivariate analyses were undertaken because of the small size of the patient groups.
A two-tailed P-value of <0.05 was taken to indicate statistical significance.
RESULTS
Baseline patient characteristics
During the study period, 55 consecutive patients underwent emergent VA-ECLS followed by the implantation of a long-term MCS device. Median (interquartile range) patient age was 51.2 (15.7) years and 44 (80%) patients were males.
Primary causes of cardiogenic shock were acute myocardial infarction in 24 (44%), idiopathic dilated cardiomyopathy in 10 (18%), dilated ischaemic cardiomyopathy in 9 (16%), acute myocarditis in 4 (7%) and other causes in 8 (15%) patients.
All patients presented initially with refractory cardiogenic shock corresponding to INTERMACS Level 1 definition. At the time of VA-ECLS implantation, median left ventricular ejection fraction was 15.0% (10.0%).
Veno-arterial extracorporeal life support
VA-ECLS was initiated in our hospital in 37 (68%) patients. The remaining 18 patients were implanted in other hospitals and transferred secondarily to our institution. Forty-six (84%) patients had peripheral and 9 (16%) had central VA-ECLS at the time of long-term MCS device implantation. The median duration of VA-ECLS before MCS implantation was 8.0 (11.0) days.
During VA-ECLS, patients were ventilated for a median time of 4.0 (10.5) days. Ten (18%) patients developed signs of pulmonary oedema while under VA-ECLS. Among these, one was on central VA-ECLS and managed medically. Nine were on peripheral ECLS and were treated as follows: medical treatment (n = 1), mechanical ventilation plus medical treatment (n = 5), mechanical ventilation plus pulmonary artery venting (n = 1) and switch to central cannulation (n = 2).
Thirteen (24%) patients suffered infectious pneumonia within 7 days preceding implantation of the long-term MCS device. At the time of implantation of the long-term MCS device, 36 (66%) were still on ventilator. Latest laboratory values at the time of long-term MCS device implantation are listed in Table 1 .
Long-term mechanical circulatory support
Twenty-three (42%) patients received isolated LVAD and 32 (58%) required the implantation of BiVADs or a TAH. Twenty-two (40%) patients received continuous flow pumps and 33 (60%) received pulsatile devices ( Table 2) .
The median duration of support under long-term device was 47.5 (168.8) days. Overall, 34 (62%) patients died while on longterm MCS after a median duration of 15.0 (71.5) days of support. Twelve (22%) patients survived to heart transplantation, 4 (7%) were weaned from long-term MCS and 5 (9%) had ongoing support at the end of the study period. Actuarial survival rates under MCS ( patients were censored at the time of transplantation or weaning) were 64.1 ± 6.6, 51.3 ± 7.1, 46.4 ± 7.2 and 39.1 ± 7.2% at 30, 60, 90 and 180 days after implantation, respectively.
Fifteen (27%) patients suffered postimplant ALI as defined previously. Of these, 11 (20%) required iterative VA-ECLS (n = 2) or VV-ECMO (n = 9) within 24 h of long-term MCS device implantation. The remaining 4 (7%) patients were managed medically using protective ventilation and nitric oxide inhalation. In these 4 patients, the PaO 2 /FiO 2 ratio was <200 and was significantly lower on postimplant days 2, 3 and 7 than in those without postimplant ALI (n = 36; Table 3 ). Mortality under long-term support was significantly higher in patients who developed postimplant ALI (13 of 15, 87%) than in those who did not (21 of 40, 53%; P = 0.03). Similarly, the estimated 30, 60 and 180 days actuarial survival rates under long-term MCS were significantly lower (P = 0.0001) in patients with postimplant ALI than in those without (respectively, 33.3 ± 12.2, 13.3 ± 8.8 and 0% vs 76.2 ± 6.9, 67.1 ± 7.9 and 50.3 ± 8.8%, Fig. 1 ). The hazard ratio for death while on support in patients who developed ALI when compared with those who did not was 3.390 (95% confidence interval, 1.636-7.026, P = 0.001).
Results of univariate risk factor analysis for postimplant ALI are reported in Table 4 . Signs of pulmonary oedema within 7 days of MCS implantation, higher levels of lactates, blood urea nitrogen, creatinine and lower levels of sodium immediately before implantation were identified as significant risk factors for postimplant ALI. Furthermore, the need for biventricular support and the number of red blood cell units transfused at the time of implantation were also significant risk factors for postimplant ALI. Of note, odd ratios for the variables 'mechanical ventilation at the time of MCS implantation' and the use of 'pulsatile devices' were not determined because of complete separation by the outcome variable (Table 1) . However, both variables were significantly associated with postimplant ALI (Table 1) .
DISCUSSION
The main findings of the present study were: (i) 27% of patients undergoing VA-ECLS bridge to implantation of a durable MCS device suffered postimplant ALI; (ii) postimplant ALI was associated with a high mortality rate (87%); (iii) risk factors for postimplant ALI included: signs of pulmonary oedema while under ECLS during the week preceding long-term device implantation; mechanical ventilation, the incomplete recovery of renal and hepatic functions and the number of red blood cell units transfused at the time of long-term device implantation; and use of pulsatile, biventricular support. Mortality under long-term support was soberingly high in this BTB patient cohort and appeared to be higher than that observed after primary MCS implantation in the French multicentric GRAM registry [8] . Although some small single-centre studies have reported similar outcomes in BTB recipients than in patients undergoing primary MCS implantation [1, 9, 10], Smedira et al. [11] have shown that sequential application of support devices was associated with marked reduced survival. Similarly, in a multivariate risk-scoring system, the need for preimplant support using short-term devices has been associated with mortality under long-term support [12] . This higher mortality in comparison with primary implants might be explained by the fact that BTB patients are probably those who have suffered the most severe cardiogenic shock. INTERMACS 1 recipients have been previously shown to have adverse outcomes under support [13] [14] [15] . Patients who require emergent VA-ECLS placement represent an even more critical sub-group within this highrisk INTERMACS 1 group, and their outcome can be expected to be particularly severe.
In some of these patients, we have noted the occurrence of fulminant pulmonary oedema immediately after the implantation of a durable MCS device. In the majority of cases, postimplant ALI was so severe that it required immediate reinstallment of VA-ECLS or VV-ECMO and was associated with extremely high mortality. We have defined this specific complication as postimplant ALI. The major criterion was its early (<48 h) occurrence after MCS implantation. Other clinical and biological parameters were derived from the recent Berlin definition of moderately severe adult respiratory distress syndrome (ARDS) [16] . Unfortunately, our study being retrospective, we had no complete physiological evaluation of pulmonary function during ECLS and after MCS device implantation to further categorize ALI.
Severe non-infectious respiratory failure is not reported as a leading cause of early morbidity or mortality after primary VAD implantation. Thus, early respiratory failure represented only 6-7% of early deaths after VAD implantation in a large patient series provided by the INTERMACS registry [13, 17] . Other authors report similarly low incidences of fatal pulmonary complications in BTB patients. However, these series were often small, and the precise causes of death were not always specified. In contrast to these series, we found a relatively high incidence of postimplant ALI in our patients undergoing a bridge-to-bridge VA-ECLS. Our study being only descriptive in nature, the precise mechanism of postimplant ALI remains to be determined. However, our results suggest that postimplant ALI has a multifactorial origin and three, probably intricated, mechanisms can be proposed. First, postimplant ALI might be the consequence of preexisting, but unrecognized, lung injury. Indeed, under VA-ECLS, lung injury might easily be underestimated or masked because of adequate oxygenation and low pulmonary artery perfusion and reveal itself only after implantation of the long-term device. Lung injury might be related to the initial cardiogenic shock. Thus, we have observed that patients still on ventilator and with persisting kidney or liver dysfunction at the time of long-term device implantation were particularly at risk for postimplant ALI. These patients had probably not recovered sufficiently from their initial multiorgan dysfunction. Alternatively, the underlying lung injury might have been acquired during ECLS such as lung oedema or infection. We found that signs of pulmonary oedema during the week preceding long-term device implantation were associated with postimplant ALI. Secondly, we have observed that patients who suffered ALI received more blood products at the time of implantation of the long-term device, suggesting that ALI was, at least in part, transfusion related. Finally, VA-ECLS results in pulmonary shunting with reduced transpulmonary blood flow [18] , and the distribution of transpulmonary blood flow might be inhomogeneous in the case of mechanical ventilation with positive pressures [19] . Low pulmonary blood flow for prolonged periods of time can induce significant pulmonary lesions. Thus, Koul et al. [20] have shown, in an experimental pig model, that normothermic total VA bypass of 18 h duration or more produces pulmonary parenchymal damage with interstitial oedema, intra-alveolar haemorrhage and pulmonary parenchymal necrosis. In this experimental model, lung injury could not be related to increased pulmonary venous pressure since the animals had normal left ventricular function. In a subsequent experiment, the same authors showed that maintaining about 25% of systemic cardiac output in the pulmonary artery allowed reducing parenchymal lesions [21] . In piglets undergoing hypoxic ventilation, Golej et al. [22] have observed higher levels of inflammatory mediators in the pulmonary alveoli of animals undergoing VA-ECLS when compared with those supported with VV-ECMO. These findings suggest that prolonged pulmonary shunting might have deleterious consequences on lung parenchyma. In our series, the duration of preimplant ECLS was significantly longer than in other published BTB series and could have exposed our recipients to more extensive pulmonary lesions. At the time of long-term MCS implantation, abrupt reestablishment of normal pulmonary blood flow through severely injured lung parenchyma probably resulted in severe ALI. This acute reperfusion injury can be expected to be even more severe when a pulsatile right VAD pushes blood under high pressure into the pulmonary vascular bed. In agreement with this hypothesis, we found that patients receiving pulsatile BiVADs were at higher risk for postimplant ALI. Interestingly, fatal pulmonary complications were reported by others to be more frequent after the implantation of pulsatile LVAD than after the implantation of continuous LVAD [17] .
As suggested by some authors, initiating MCS early with a single definitive device may improve survival to, and after, transplantation [11] . However, in some patients, a BTB strategy appears to be the only therapeutic option. Our experience shows that patients who undergo a VA-ECLS BTB are at risk of postimplant ALI. To reduce this risk, we propose that the duration of VA-ECLS should be kept as short as possible. However, every effort should be made to wean patients from mechanical ventilation and achieve as complete as possible end-organ recovery. Pulmonary congestion under ECLS should be treated aggressively before the implantation of a long-term device. For patients requiring biventricular support, protocols of progressive pressure increase on the right side with the objective of avoiding brutal re-establishment of transpulmonary flow at the time of MCS implantation need to be evaluated in future studies.
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APPENDIX. CONFERENCE DISCUSSION
Dr T. Hrapkowicz (Zabrze, Poland): As we know, extracorporeal membrane oxygenation is recently widely used as a first-choice circulatory support in patients in acute cardiogenic shock. We know that veno-arterial ECMO as short-term support has many disadvantages, but sometimes it is the only option, especially in the very difficult INTERMACS 1 patients, in an emergency situation. As you have very clearly shown, one of the most devastating problems is acute respiratory failure, even after implantation of long-term mechanical support.
In your observations, the presence of kidney and of liver injury, were the important risk factors for post-implant respiratory failure, but also pre-existing lung injury might play the basic role. The other thing you have concluded is that in the patients with post-implant lung injury, biventricular assist devices most often have been used. My first question is: do you have some explanation why biventricular assist device support was associated with worse results?
Dr Boulate: Patients who developed acute lung injury had BiVAD support more frequently, probably because they had more severe cardiogenic shock at the beginning, which is logical when you look at their more severe end organ failure, and at the longer duration of mechanical ventilation, during the period of veno-arterial extracorporeal life support. The second problem related to biventricular support is that you abruptly restore a normal antegrade pulsatile blood flow in a pulmonary circulation which has been shunted by the VA-ECLS. So that also could be a factor affecting the onset of the acute lung injury.
Dr Hrapkowicz: As you said, arterial ECMO reduces the transpulmonary blood flow due to pulmonary shunting. In your study, in some of the patients with respiratory failure after implantion of mechanical circulatory support, veno-arterial ECMO has been used. Could you explain why in these cases you didn't decide to use veno-venous ECMO?
Dr Boulate: Of 15 patients who developed acute lung injury, 11 were treated with veno-venous or veno-arterial ECMO. Of these 11 patients, seven were placed under veno-venous ECMO and only three had veno-arterial ECMO placement. The main reason was that these patients had placement of their long-term device without weaning from the veno-arterial ECMO and at the onset of pulmonary oedema, we simply kept the veno-arterial ECMO. These patients were not immediately switched to veno-venous ECMO. If veno-arterial ECMO had already been removed at the time of acute lung injury, we performed veno-venous ECMO placement.
Dr Hrapkowicz: Lastly, in these patients with respiratory failure, was pulmonary oedema the only respiratory complication or did you also observe others such as pulmonary infection or pulmonary embolism, which may be relatively common during ECMO support?
Dr Boulate: During the VA-ECLS period, we noted pneumonia in several patients, but there was no significant difference between the two groups, so it was not identified as an independent risk factor in our analysis. We didn't observe any pulmonary embolism.
Dr C. Schmid (Regensburg, Germany): I would like to come back to your strategy, which was not quite clear for me. If you have a lot of biventricular support and you have, let's say, a Thoratec, you can easily just put an oxygenator in any line. This is very simple. But if you have a patient on an LVAD, to my mind it is important first to look at the right heart function. If it is pure respiratory failure, we would always go for a veno-venous ECMO, because if you use veno-arterial ECMO from the femoral side, you may have an undersaturation of the cerebrum and the heart itself. The peripheral cannulation then should be over the subclavian and axillary vessels. And as you just said, if you have an immediate post-cardiotomy problem, why not switch to a temporary right heart assist, with an oxygenator included, which you can remove without reopening the chest. It is far simpler. Because if you are just putting or leaving a veno-arterial line on the femoral, of course you have some kind of temporary right heart support, but you do not solve the respiratory problem.
Dr Boulate: I agree with what you said. Patients with isolated right heart failure were excluded from the study. We included only patients with early respiratory failure. There were only three patients who had veno-arterial ECMO for the treatment of the pulmonary oedema, and four others had medical treatment.
Dr A. Rastan (Rotenberg, Germany): So for me the story seems obvious. The sicker the patient, the worse is his outcome. It is a continuum. The VAD patients, of course, are more likely to have multi-organ failure, including lung injury, and they also require biventricular support. Thus it is not surprising that so-called 'bad' patients have a worse outcome.
I am just asking you for the conclusions you have drawn from your data. One should be, for example, that a patient who is in manifest multi-organ failure, including lung injury, shouldn't be a candidate for an LVAD or a BIVAD. Is this the message you have drawn from your experience?
Dr Boulate: The consequence for clinical practice is that, firstly, we have shown that pulmonary oedema while on veno-arterial extracorporeal life support was a risk factor. So it is very important to know this and to unload the left ventricle as much as possible, with inotropic support, intra-aortic balloon counterpulsation, and if it is not enough to recover the oedema, you must add direct venting lines or switch to central ECMO or double central ECMO. This is one of the most important messages.
The second one is to make the first bridge as short as possible, because in our study, the duration of the VA ECLS period was 11 days, whereas in the literature in most of the series of bridge-to-bridge strategy, the duration was less than five days and pulmonary oedema was not clearly described. So probably the prolongation of the duration of the pulmonary circulation shunting creates lung injury, which is uncovered when you implant the long-term device. So this period must be kept as short as possible. And if it is not possible because the end-organ recovery is not achieved, you probably must prolong the first bridge with VA-ECLS and extubate the patient, because all the patients who developed acute lung injury were not extubated at the time of the long-term MCS implantation.
